drugset / Trial / NCT03466671

A Trial of TTA-121 on Autism Spectrum Disorder

NCT03466671 ↗

RandomizedCrossoverQuadruple-blindTreatment

Summary

To test efficacy and safety of a novel nasal spray of oxytocin on social deifies in autism spectrum disorder, and To compare effect sizes of different doses

Timeline

Start
2018-02-27
Primary completion
2020-03-16
Completion
2020-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 3 iu Intranasal
Subject Oxytocin Peptide 10 iu Intranasal